Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy by Bhindi, Bimal et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Identification of the best complete blood count-based predictors for bladder
cancer outcomes in patients undergoing radical cystectomy
Bhindi, Bimal; Hermanns, Thomas; Wei, Yanliang; Yu, Julie; Richard, Patrick O; Wettstein, Marian S;
Templeton, Arnoud; Li, Kathy; Sridhar, Srikala S; Jewett, Michael A S; Fleshner, Neil E; Zlotta,
Alexandre R; Kulkarni, Girish S
Abstract: BACKGROUND: We sought to determine which parsimonious combination of complete blood
count (CBC)-based biomarkers most efficiently predicts oncologic outcomes in patients undergoing radical
cystectomy (RC) for bladder cancer (BC). METHODS: Using our institutional RC database (1992-2012),
nine CBC-based markers (including both absolute cell counts and ratios) were evaluated based on pre-
treatment measurements. The outcome measures were recurrence-free survival (RFS), cancer-specific
survival (CSS), and overall survival (OS). Time-dependent receiver-operating characteristics curves were
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Background: We sought to determine which parsimonious combination of complete blood count (CBC)-based biomarkers most
efficiently predicts oncologic outcomes in patients undergoing radical cystectomy (RC) for bladder cancer (BC).
Methods: Using our institutional RC database (1992–2012), nine CBC-based markers (including both absolute cell counts and
ratios) were evaluated based on pre-treatment measurements. The outcome measures were recurrence-free survival (RFS), cancer-
specific survival (CSS), and overall survival (OS). Time-dependent receiver-operating characteristics curves were used to
characterise each biomarker. The CBC-based biomarkers, along with several clinical predictors, were then considered for inclusion
in predictive multivariable Cox models based on the Akaike Information Criterion.
Results: Our cohort included 418 patients. Neutrophil–lymphocyte ratio (NLR) was the only biomarker satisfying criteria for
inclusion into all models, independently predicting RFS (HR per 1-log unit¼ 1.52, 95% CI¼ 1.17–1.98, P¼ 0.002), CSS (HR¼ 1.47,
95% CI¼ 1.20–1.80, Po0.001), and OS (HR¼ 1.56, 95% CI¼ 1.16–2.10, P¼ 0.004). Haemoglobin was also independently predictive
of CSS (HR per 1 g/dl¼ 0.91, 95% CI¼ 0.86–0.95, Po0.001) and OS (HR¼ 0.90, 95% CI¼ 0.88–0.93, Po0.001), but not RFS.
Conclusions: Among CBC biomarkers studied, NLR was the most efficient marker for predicting RFS, whereas NLR and
haemoglobin were most efficient in predicting CSS and OS. NLR and haemoglobin are promising, cost-effective, independent
biomarkers for predicting oncologic BC outcomes following RC.
Condensed abstract: Various CBC-based biomarkers have separately been shown to be predictive of oncologic outcomes in
patients undergoing cystectomy for BC. Our study evaluated these biomarkers, and determined that NLR is the best CBC-based
biomarker for predicting RFS, whereas NLR and haemoglobin are most efficient for predicting CSS and OS.
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Radical cystectomy (RC) with pelvic lymphadenectomy remains
the standard treatment for patients with localised muscle-invasive
bladder cancer (MIBC) and for BCG-refractory non-muscle
invasive bladder cancer (NMIBC; Clark et al, 2013). Unfortunately,
10-year cancer-specific survival (CSS) rates are only B70%
(Cookson et al, 1997) and 40–60% (Stein et al, 2001; Shariat
et al, 2006) for high-risk NMIBC and for MIBC, respectively. More
aggressive approaches can be used to improve oncological
outcomes, namely neo-adjuvant or adjuvant chemotherapy for
patients with MIBC (Grossman et al, 2003), and early RC for
patients with high-risk NMIBC (Kulkarni et al, 2010). However,
the non-selective use of these approaches carries the risk of
overtreatment, particularly among patients with favourable prog-
noses. Treatment decision-making is oftentimes challenging,
particularly because risk stratification based on clinical
and pathologic parameters is insufficient (Shariat et al, 2007;
Canter et al, 2011).
Peripheral neutrophil–lymphocyte ratio (NLR) is a novel
prognostic biomarker in bladder cancer (BC). Elevated NLR has
been shown to be predictive of adverse oncologic outcomes in
patients with NMIBC (Can et al, 2012; Kaynar et al, 2014; Mano
et al, 2015) and MIBC (Gondo et al, 2012; Krane et al, 2013;
Hermanns et al, 2014; Potretzke et al, 2014; Viers et al, 2014).
Several other complete blood count (CBC)-based prognostic
biomarkers have also been described for BC, including absolute
platelet count (Can et al, 2012; Todenhofer et al, 2012; Moschini
et al, 2014), haemoglobin, (Gondo et al, 2012; Gierth et al, 2015),
and lymphocyte–monocyte ratio (LMR; Temraz et al, 2014). In
addition, platelet–lymphocyte ratio (PLR) has also shown to
predict oncologic outcomes for other cancer sites (Azab et al, 2013;
Feng et al, 2014), but studies of its prognostic value in BC have yet
to be reported.
There is likely some degree of overlap between these CBC-based
biomarkers, and some may be redundant. For future studies and
potential clinical use, a parsimonious combination of these
biomarkers is required. Our objective was thus to determine
which combination of these biomarkers most efficiently predicts
oncologic outcomes in patients undergoing RC for BC.
MATERIALS AND METHODS
Patients and data collection. We performed a retrospective
cohort study of patients undergoing RC for urothelial carcinoma
of the bladder identified using our institutional database (1992–
2012), which has been described in detail in prior reports (Bhindi
et al, 2014; Hermanns et al, 2014). Institutional research ethics
approval was obtained. Clinical and pathologic data were obtained
using chart review. Mortality data were obtained using the Princess
Margaret Hospital Cancer Registry. Exclusion criteria were
unavailable CBCs and differentials (n¼ 20), history of conditions
that could potentially affect blood cell lines (leukemia: n¼ 2,
human immunodeficiency virus infection: n¼ 1, malignant
lymphoma: n¼ 3, connective tissue disease: n¼ 4) and RC done
for salvage following failed chemo-radiation (n¼ 20).
Primary study exposure. The date of treatment initiation was
defined as the date of RC or date of initiation of neo-adjuvant
chemotherapy, as applicable. Complete blood count collections
were performed usually a week before treatment initiation (median
of 6 days, IQR¼ 2–10 days) as part of the routine pre-treatment
clinical assessment. Clinical notes were reviewed to rule out any
symptoms or signs of infection around the time of CBCs.
Candidate biomarkers considered in our study included
haemoglobin, individual cell counts (absolute neutrophil, lympho-
cyte, monocyte, and platelet counts), and the cell count ratios NLR,
monocyte–lymphocyte ratio, LMR, and PLR.
Clinical follow-up and outcomes. Patients were generally seen in
follow-upB6–8 weeks following discharge, and every 3–6 months
thereafter for physical examination and imaging to assess for
hydronephrosis and cancer recurrence. Visits were further spaced
apart over time based on individual physician’s practice patterns
and clinical suspicion. The study outcomes were recurrence-free
(RFS), CSS, and overall survival (OS) from time of treatment
initiation. Patients were censored if event-free at their most recent
clinic visit, up to 31 October 2013.
Statistical analysis. Descriptive statistics were used to summarise
cohort characteristics and distributions of CBC-based predictors.
Complete blood count-based predictors with skewed distributions
were log-transformed to improve model fit.
An initial assessment of CBC-based predictors was performed
using univariate time-dependent receiver operating characteristics
(ROC) curves for each outcome measure at 12-month intervals for
5 years (Heagerty and Zheng, 2005). To avoid issues with multi-
collinearity in ensuing analytic steps, similar predictors were
compared and only those with superior areas under the ROC
curves were retained for further evaluation.
For each of the retained predictors, Kaplan–Meier analyses with
the log-rank test and univariate Cox regression analyses were
performed in order to confirm the predictive value seen in other
studies (Can et al, 2012; Gondo et al, 2012; Todenhofer et al, 2012;
Azab et al, 2013; Krane et al, 2013; Feng et al, 2014; Hermanns
et al, 2014; Moschini et al, 2014; Potretzke et al, 2014; Temraz et al,
2014; Viers et al, 2014; Gierth et al, 2015; Mano et al, 2015).
Next, we created multivariable Cox proportional hazards
models considering all possible combinations of the retained
CBC-based predictors and clinical parameters (age, gender, heavy
smoking status defined asX30 pack-years, Charlson co-morbidity
index, hydronephrosis, concurrent carcinoma in situ, pathological
T-stage, and pathological N-stage, lymphovascular invasion (LVI)
and positive surgical margin status). A robust sandwich covariance
matrix estimator was used to account for clustering of outcomes by
surgeon (Lin and Wei, 1989). Optimal models were selected as
those that minimised the Akaike Information Criterion (AIC),
representing parsimonious models that offered the best fit to the
data with the fewest number of predictors. The partial
log-likelihood test was used to compare final predictive models
with and without the selected CBC-based predictors to determine if
these predictors significantly improved model fit.
Statistical analyses were performed using SAS v9.3
(SAS Institute Inc, Cary, NC, USA). All tests were two-sided with
P-values o0.05 considered statistically significant.
RESULTS
The final cohort included 418 patients with a median age of 70
years (IQR¼ 61–76 years). Pathological extra-vesical extension was
present in 191 patients (46%), and nodal metastases were present
in 115 patients (27%). Cohort characteristics are further described
in Table 1. During a median follow-up of 40 months (IQR¼ 14–72
months), there were 136 cancer recurrences, 107 BC-related
deaths, and 177 deaths overall.
The AUCs of the time-dependent ROC curve analyses, used to
identify the best predictors among those that are similar to each
other, are shown in Supplementary Table 1. The AUCs for NLR
were superior to those for absolute neutrophil and lymphocyte
counts, whereas the AUCs for PLR were superior to those for
absolute platelet and lymphocyte counts. The AUCs for LMR were
superior to those for monocyte–lymphocyte ratio, absolute
monocyte count and absolute lymphocyte count. There were no
predictors similar to haemoglobin. Thus, in subsequent analyses,
only haemoglobin, NLR, LMR, and PLR were retained, whereas
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those predictors deemed similar and inferior were eliminated in
order to avoid collinearity.
In Kaplan–Meier analyses, higher NLR and PLR values (above
median), and lower haemoglobin and LMR values (below median)
were shown to be associated with worse RFS, CSS, and OS (all
Po0.05, except for the association between haemoglobin and RFS
where P¼ 0.08; see Figure 1). These findings were replicated in the
univariate Cox-regression analyses (Table 2). Increasing NLR was
associated with worse RFS (HR per 1-log unit¼ 1.49, 95%
CI¼ 1.22–1.81, Po0.001), CSS (HR per 1-log unit¼ 1.58,
95% CI¼ 1.32–1.90, Po0.001), and OS (HR per 1-log unit¼ 1.74,
95% CI¼ 1.43–2.11, Po0.001). Increasing PLR was also associated
with worse RFS, CSS, and OS. Increasing haemoglobin level was
associated with improved RFS (HR per 1 g/dl¼ 0.90, 95%
CI¼ 0.86–0.94, Po0.001), CSS (HR per 1 g/dl¼ 0.87,
95%CI¼ 0.82–0.91, Po0.001), and OS (HR per 1 g/dl¼ 0.84,
95% CI¼ 0.82–0.87, Po0.001). Increasing LMR was also
associated with better RFS, CSS, and OS.
Final parsimonious multivariable models, created based on
minimising AIC values, are shown in Table 3. NLR (HR per 1-log
unit¼ 1.52, 95% CI¼ 1.17–1.98, P¼ 0.002) was the only CBC-
based predictor retained for inclusion in the model for RFS, along
with T-stage, N-stage, LVI, and positive surgical margins. NLR
(HR per 1-log unit¼ 1.47, 95% CI¼ 1.20–1.80, Po0.001) and
haemoglobin (HR per 1 g/dl¼ 0.91, 95% CI¼ 0.86–0.95, Po0.001)
were the only CBC-based predictors retained in the model for CSS,
along with T-stage, N-stage, LVI, and positive surgical margins.
Last, NLR (HR per 1-log unit HR¼ 1.56, 95% CI¼ 1.16–2.10,
P¼ 0.004) and haemoglobin (HR per 1g/dl¼ 0.90, 95% CI¼ 0.88–0.93,
Po0.001) were the only CBC-based predictors retained in the
model for OS, along with age, Charlson co-morbidity index,
T-stage, N-stage, LVI, and positive surgical margins.
Upon comparing final models with and without the selected
CBC-based predictors, it was found that the inclusion of NLR
significantly improved the goodness-of-fit of the model for RFS
(P¼ 0.014), whereas the inclusion of NLR and haemoglobin
significantly improved the goodness-of-fit of the models for CSS
(P¼ 0.008) and OS (Po0.001), compared with respective models
with clinical and pathologic parameters only (see Supplementary
Table 2 for details).
DISCUSSION
Although the potential role of inflammation in cancer was originally
proposed by Rudolph Virchow in the nineteenth century, it is only
during the past 10–15 years that a deeper understanding has
emerged of the impact of inflammation in carcinogenesis and cancer
progression (Grivennikov et al, 2010; Hanahan and Weinberg,
2011). Recently, there has been growing interest in using CBC-based
measures as BC biomarkers, with numerous studies separately
reporting on the impact of individual components of the CBC on
RC outcomes (Can et al, 2012; Gondo et al, 2012; Todenhofer et al,
2012; Azab et al, 2013; Krane et al, 2013; Feng et al, 2014; Hermanns
et al, 2014; Moschini et al, 2014; Potretzke et al, 2014; Temraz et al,
2014; Viers et al, 2014; Gierth et al, 2015). With growing data
supporting the prognostic value of various CBC-based biomarkers,
we sought to elucidate which of these variables would ultimately
possess the greatest potential in the RC population.
In our study, NLR was the sole CBC-derived biomarker to be
independently predictive of RFS, CSS, and OS. This is consistent
with existing literature, with NLR being the most frequently reported
CBC-derived biomarker in BC (Can et al, 2012; Gondo et al, 2012;
Krane et al, 2013; Hermanns et al, 2014; Kaynar et al, 2014;
Potretzke et al, 2014; Viers et al, 2014; Mano et al, 2015). NLR has
been shown to predict muscle-invasion upon transurethral resection
(Can et al, 2012; Kaynar et al, 2014), recurrence, and progression for
NMIBC (Mano et al, 2015), upstaging at the time of RC (Krane et al,
2013; Hermanns et al, 2014; Potretzke et al, 2014; Viers et al, 2014),
and worse oncologic outcomes following RC (Gondo et al, 2012;
Krane et al, 2013; Hermanns et al, 2014; Viers et al, 2014).
NLR also has a strong biological rationale, in the context of the
role of immunity and inflammation in cancer development and
progression (Grivennikov et al, 2010; Hanahan and Weinberg,
2011). Conceptually, NLR represents the ratio of the innate
immune response (i.e., neutrophils) to the adaptive immune
response (i.e., lymphocytes). Neutrophils assemble at the margins
of pre-malignant lesions and promote carcinogenesis through
various mechanisms, including: (i) producing reactive oxygen
Table 1. Cohort characteristics
Cohort characteristics Total n¼418
Patient characteristics
Age in years, median (IQR) 70 (61–76)
Female sex, n (%) 96 (23.0)
Heavy smoking (X30pack-years), n (%) 133 (32)
BMI (kg/m2), median (IQR) 27 (24–30)
Charlson co-morbidity index, median (IQR) 1 (0–2)
Disease characteristics
Hydronephrosis, n (%) 117 (28)
Concurrent CIS, n (%) 188 (45)
T-stage, n (%)
pT0 25 (6)
pTa/Tis/T1/T2 202 (48)
pT3/T4 191 (46)
N-stage, n (%)
pN0 282 (68)
pNþ 115 (27)
pNx 21 (5)
Lymphovascular invasion, n (%) 141 (34)
Positive surgical margina, n (%) 33 (8)
Other treatment characteristics
Year of surgery, n (%)
1992–2005 208 (50)
2006–2012 210 (50)
Continent diversion, n (%) 89 (21)
Node total, median (IQR) 12 (7–19)
Neo-adjuvant chemotherapy, n (%) 28 (7)
Adjuvant chemotherapy, n (%) 87 (20)
Salvage chemotherapy, n (%) 54 (13)
CBC-based parameters
Haemoglobin (g/dl), median (IQR) 13.2 (11.6–14.5)
WBC (109/l), median (IQR) 7.6 (6.0–9.1)
Neutrophils ( 109/l), median (IQR) 4.8 (3.8–6.5)
Monocytes ( 109/l), median (IQR) 0.6 (0.5–0.7)
Lymphocytes ( 109/l), median (IQR) 1.7 (1.3–2.1)
Platelets (109/l), median (IQR) 253 (204–303)
NLR, median (IQR) 2.9 (2.1–4.3)
MLR, median (IQR) 0.36 (0.26–0.50)
LMR, median (IQR) 2.8 (2.0–3.8)
PLR, median (IQR) 150 (103–202)
Abbreviations: BMI¼body mass index; CBC¼ complete blood count; CIS¼ carcinoma
in situ; IQR= interquartile range; LMR= lymphocyte monocyte ratio; MLR=monocyte
lymphocyte ratio; NLR=neutrophil lymphocyte ratio; PLR=platelet lymphocyte ratio;
WBC=white blood cell count.
aPositive surgical margins rates are based on permanent sections (paraffin-embedded) and
exclude ureteral carcinoma in-situ.
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Figure 1. Kaplan–Meier analyses of associations between CBC-based predictors (above vs below median for haemoglobin (row 1), neutrophil–
lymphocyte ratio (row 2), lymphocyte–monocyte ratio (row 3), and platelet–lymphocyte ratio (row 4)) and oncologic outcomes.
Table 2. Univariate associations between predictors and oncologic outcomes following radical cystectomy
Recurrence-free survival Cancer-specific survival Overall survival
Parameter HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Haemoglobin, per 1g/dl 0.90 (0.86–0.94) o0.001 0.87 (0.82–0.91) o0.001 0.84 (0.82–0.87) o0.001
Neutrophil–lymphocyte ratio, per 1-log unita 1.49 (1.22–1.81) o0.001 1.58 (1.32–1.90) o0.001 1.74 (1.43–2.11) o0.001
Lymphocyte–monocyte ratio, per 1-log unita 0.66 (0.55–0.79) o0.001 0.69 (0.53–0.91) 0.009 0.70 (0.55–0.88) 0.002
Platelet–lymphocyte ratio, per 100 units 1.22 (1.08–1.38) 0.002 1.21 (1.05–1.41) 0.01 1.16 (1.02–1.33) 0.03
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio.
aLog-transformed.
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species capable of inducing DNA damage and genomic instability,
(ii) promoting the secretion of various growth factors that enhance
the proliferation of mutated cells, (iii) promoting angiogenesis, and
(iv) promoting metastasis (Grivennikov et al, 2010). Meanwhile,
T and B lymphocytes are capable of recognising tumour antigens
and may aid in an anti-tumour response through cell-mediated
and antibody-dependent cytotoxicity, respectively, although in the
majority of cases, this response alone is insufficient to restrain
tumour growth (Grivennikov et al, 2010). In our study, circulating
NLR had greater predictive value than either absolute neutrophil or
lymphocyte counts alone, suggesting that both counts are
important and that the ratio is the most informative.
Haemoglobin level also added predictive value for CSS and OS,
independently of NLR and other clinic-pathologic predictors.
Anaemia has been shown to be associated with worse RFS, CSS,
and OS following RC (Gierth et al, 2015). Anaemia is likely
multifactorial in this population. It may be in part due to blood loss
from tumour-related bleeding. There may also be a component of
anaemia of chronic disease (also known as anemia of chronic
inflammation), which is driven by acute and/or chronic immune
system activation (Weiss and Goodnough, 2005), and in turn may
be a systemic effect of BC or of other co-morbid diseases.
Secondary thrombocytosis (also called reactive thrombocytosis) is
most often the result of acute or chronic inflammatory conditions,
infections, or malignancies. This is mediated by pro-inflammatory
cytokines such as interleukin (IL)-1, IL-6, IL-11, and tumour
necrosis factor-a, among others (Bleeker and Hogan, 2011). In
patients undergoing RC, platelet count was associated with more
advanced disease (Moschini et al, 2014) and worse CSS (Todenhofer
et al, 2012). In our study, PLR, compared with absolute platelet
counts, showed greater discrimination for oncologic outcomes
following RC. Moreover, we demonstrated for the first time, the
potential ability of PLR as a prognostic indicator for RC. However,
PLR did not add value to multivariable models when NLR,
haemoglobin level, and clinical predictors were included.
Similar to neutrophils, macrophages (differentiated monocytes)
can support tumour-related angiogenesis and cell migration
(Temraz et al, 2014). Lower lymphocyte–monocyte ratio (LMR)
was demonstrated in one study (Temraz et al, 2014) to
be associated with reduced disease-free survival and OS. The
Kaplan–Meier analyses in our study are consistent with this
finding. However, as was the case for PLR, LMR was not retained
as an independent predictor of oncologic outcomes once other
variable were considered.
To our knowledge, the present study is the first to compare various
CBC-based biomarkers in order to determine which parsimonious
combination most efficiently predicts oncologic outcomes in BC. Now
that it is more clear which predictors are most efficient, it is possible to
formally evaluate how NLR and haemoglobin can best be employed to
guide clinical decision-making.
Data supporting a potential clinical role for CBC-based
predictors, particularly NLR, are emerging. For example, NLR can
risk-stratify patients with clinical NMIBC into a group with excellent
outcomes upon early cystectomy (490% 5-years CSS) and a group
with similar oncologic outcomes to patients with clinical MIBC
(B60% 5-year CSS; Hermanns et al, 2014). This may be helpful in
guiding the use of early cystectomy. Also, change in NLR during
neo-adjuvant chemotherapy can be helpful in predicting patholo-
gical response (Seah et al, 2015). Last, NLR can also further risk-
stratify patients beyond pathological stage, which may be helpful in
guiding the use of adjuvant chemotherapy (Hermanns et al, 2014).
Our study is not without limitations. First, this is a single-
institution retrospective observational study. Second, we did not
routinely measure CBCs at regular intervals post-RC, and therefore
cannot comment on whether changes in CBC-based biomarkers
have predictive value. Given the myriad factors that can affect CBC
levels postoperatively, it is unlikely that immediate post-RC CBC
components will yield prognostic value. Third, our cohort included
very few patients receiving neo-adjuvant chemotherapy, and
therefore further studies are needed to evaluate how CBC-based
biomarkers are affected by neo-adjuvant chemotherapy, and
whether CBC-based biomarkers can predict response to neo-
adjuvant chemotherapy. Fourth, data C-reactive protein-levels
were not available in our retrospective cohort. Future studies are
warranted to evaluate if C-reactive protein provides additional
prognostic value to NLR and haemoglobin levels. Last, it is unclear
whether our findings in patients undergoing RC are generalisable
to all BC patients. Further studies are warranted in patients with
low-intermediate risk NMIBC.
CONCLUSION
Several CBC-based biomarkers are reported to have prognostic
value in BC. They are cost-effective and widely accessible. Our
study has identified NLR as the most efficient marker for
predicting RFS, whereas NLR and haemoglobin together were
found to be the most efficient for predicting CSS and OS. These
predictors can be helpful along with other known predictors such
as clinical and pathologic stage and grade. It is not practical for
clinicians to use redundant biomarkers, and parsimony is essential.
This study hopes to guide the focus of future research on CBC-
based predictors. Further studies should be directed at how NLR
and haemoglobin can help guide clinical decision-making in this
complex patient population.
Table 3. Final parsimonious multivariable models for
recurrence-free, cancer-specific, and overall survival
Parameter HR (95% CI) P-value
Model for recurrence-free survivala
T-stage, pT3-4 vs pT0-2 1.58 (1.03–2.42) 0.03
N-stage, Nþ vs N0 2.15 (2.82–2.53) o0.0001
Lymphovascular invasion 1.72 (1.04–2.86) 0.03
Positive surgical margin 2.16 (1.42–3.28) o0.001
Neutrophil–lymphocyte ratio, per
1-unit increaseb
1.52 (1.17–1.98) 0.002
Model for cancer-specific survivalc
T-stage, pT3-4 vs pT0-2 1.67 (1.07–2.62) 0.02
N-stage, Nþ vs N0 2.13 (1.27–3.57) 0.004
Lymphovascular invasion 1.75 (0.94–3.28) 0.08
Positive surgical margin 1.82 (0.88–3.79) 0.11
Haemoglobin (per 1 g/l increase) 0.91 (0.86–0.95) o0.001
Neutrophil–lymphocyte ratio, per
1-unit increaseb
1.47 (1.20–1.80) o0.001
Model for overall survivald
Age, per 1 year increase 1.03 (1.01–1.04) 0.008
Charlson co-morbidity index, per
1-point increase
1.16 (1.03–1.32) 0.01
T-stage, pT3-4 vs pT0-2 1.42 (0.83–2.45) 0.20
N-stage, Nþ vs N0 1.55 (1.12–2.14) 0.008
Lymphovascular invasion 1.74 (1.03–2.93) 0.04
Positive surgical margin 1.86 (0.90–3.82) 0.09
Haemoglobin, per 1g/dl increase 0.90 (0.88–0.93) o0.001
Neutrophil–lymphocyte ratio, per
1-unit increaseb
1.56 (1.16–2.10) 0.004
Abbreviations: AIC¼Akaike Information Criterion; CI¼ confidence interval; HR¼hazard
ratio.
aLikelihood ratio omnibus test: w2¼ 84.8, dF¼ 5, Po0.001; AIC¼ 1407.0.
bVariable was log-transformed, and therefore hazard ratios represent effect per 1 log-unit.
cLikelihood ratio omnibus test: w2¼ 68.9, dF¼ 6, Po0.001; AIC¼ 1101.6.
dLikelihood ratio omnibus test: w2¼ 111.0, dF¼ 8, Po0.001; AIC¼ 1780.7.
Blood count biomarkers for cystectomy BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.432 211
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, Habeshy A, Picon A,
Bloom S (2013) Pretreatment neutrophil/lymphocyte ratio is superior to
platelet/lymphocyte ratio as a predictor of long-term mortality in breast
cancer patients. Med Oncol 30(1): 432.
Bhindi B, Yu J, Kuk C, Sridhar SS, Hamilton RJ, Finelli A, Jewett MA, Evans A,
Fleshner NE, Zlotta AR, Kulkarni GS (2014) The importance of surgeon
characteristics on impacting oncologic outcomes for patients undergoing
radical cystectomy. J Urol 192(3): 714–720.
Bleeker JS, Hogan WJ (2011) Thrombocytosis: diagnostic evaluation,
thrombotic risk stratification, and risk-based management strategies.
Thrombosis 2011: 536062.
Can C, Baseskioglu B, Yilmaz M, Colak E, Ozen A, Yenilmez A (2012)
Pretreatment parameters obtained from peripheral blood sample predicts
invasiveness of bladder carcinoma. Urol Int 89(4): 468–472.
Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F,
Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA (2011)
Clinicopathological outcomes after radical cystectomy for clinical T2
urothelial carcinoma: further evidence to support the use of neoadjuvant
chemotherapy. BJU Int 107(1): 58–62.
Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW,
Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC,
Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP,
Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG,
Dwyer M, Ho M. National Comprehensive Cancer N (2013) Bladder cancer.
J Natl Compr Cancer Netw 11(4): 446–475.
Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR (1997)
The treated natural history of high risk superficial bladder cancer: 15-year
outcome. J Urol 158(1): 62–67.
Feng JF, Huang Y, Chen QX (2014) Preoperative platelet lymphocyte ratio (PLR)
is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in
patients with esophageal squamous cell carcinoma.World J Surg Oncol 12: 58.
Gierth M, Mayr R, Aziz A, Krieger S, Wullich B, Pycha A, Lodde M, Salvadori U,
Brundl J, Fritsche HM, Hofstadter F, Pawlik MT, Otto W, May M, Burger M,
Denzinger S (2015) Preoperative anemia is associated with adverse outcome
in patients with urothelial carcinoma of the bladder following radical
cystectomy. J Cancer Res Clin Oncol 141: 1819–1826.
Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K,
Yoshioka K, Ohori M, Hatano T, Tachibana M (2012) Prognostic value of
neutrophil-to-lymphocyte ratio and establishment of novel preoperative
risk stratification model in bladder cancer patients treated with radical
cystectomy. Urology 79(5): 1085–1091.
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and
cancer. Cell 140(6): 883–899.
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ,
Trump DL, deVere White RW, Sarosdy MF, Wood Jr. DP, Raghavan D,
Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared
with cystectomy alone for locally advanced bladder cancer. N Engl J Med
349(9): 859–866.
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation.
Cell 144(5): 646–674.
Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC
curves. Biometrics 61(1): 92–105.
Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A,
Jewett MA, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS (2014)
Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse
outcomes in patients undergoing radical cystectomy for urothelial carcinoma
of the bladder. Br J Cancer 111(3): 444–451.
Kaynar M, Yildirim ME, Badem H, Cavis M, Tekinarslan E, Istanbulluoglu MO,
Karatas OF, Cimentepe E (2014) Bladder cancer invasion predictability
based on preoperative neutrophil-lymphocyte ratio. Tumour Biol 35(7):
6601–6605.
Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK (2013)
Preoperative neutrophil/lymphocyte ratio predicts overall survival and
extravesical disease in patients undergoing radical cystectomy. J Endourol
27(8): 1046–1050.
Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W,
Kamat A, Zlotta A (2010) An updated critical analysis of the treatment
strategy for newly diagnosed high-grade T1 (previously T1G3) bladder
cancer. Eur Urol 57(1): 60–70.
Lin D, Wei L-J (1989) The robust inference for the Cox proportional hazards
model. J Am Stat Assoc 84(408): 1074–1078.
Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, Rubinstein J,
Halachmi S (2015) Neutrophil-to-lymphocyte ratio predicts progression
and recurrence of non-muscle-invasive bladder cancer. Urol Oncol 33(2):
67 e1–67 e7.
Moschini M, Suardi N, Pellucchi F, Rocchini L, La Croce G, Capitanio U,
Briganti A, Damiano R, Montorsi F, Colombo R (2014) Impact of
preoperative thrombocytosis on pathological outcomes and survival in
patients treated with radical cystectomy for bladder carcinoma. Anticancer
Res 34(6): 3225–3230.
Potretzke A, Hillman L, Wong K, Shi F, Brower R, Mai S, Cetnar JP, Abel EJ,
Downs TM (2014) NLR is predictive of upstaging at the time of radical
cystectomy for patients with urothelial carcinoma of the bladder. Urol
Oncol 32(5): 631–636.
Seah JA, Leibowitz-Amit R, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM,
Sridhar SS (2015) Neutrophil-lymphocyte ratio and pathological response
to neoadjuvant chemotherapy in patients with muscle-invasive bladder
cancer. Clin Genitourin Cancer 13(4): e229–e233.
Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE,
Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP
(2006) Outcomes of radical cystectomy for transitional cell carcinoma
of the bladder: a contemporary series from the Bladder Cancer
Research Consortium. J Urol 176(6 Pt 1): 2414–2422; discussion 2422.
Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ,
Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y (2007) Discrepancy
between clinical and pathologic stage: impact on prognosis after radical
cystectomy. Eur Urol 51(1): 137–149; discussion 149-51.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E,
Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG
(2001) Radical cystectomy in the treatment of invasive bladder
cancer: long-term results in 1054 patients. J Clin Oncol 19(3):
666–675.
Temraz S, Mukherji D, Farhat ZA, Nasr R, Charafeddine M, Shahait M,
Wehbe MR, Ghaida RA, Gheida IA, Shamseddine A (2014) Preoperative
lymphocyte-to-monocyte ratio predicts clinical outcome in patients
undergoing radical cystectomy for transitional cell carcinoma of the
bladder: a retrospective analysis. BMC Urol 14: 76.
Todenhofer T, Renninger M, Schwentner C, Stenzl A, Gakis G (2012) A new
prognostic model for cancer-specific survival after radical cystectomy
including pretreatment thrombocytosis and standard pathological risk
factors. BJU Int 110(11 Pt B): E533–E540.
Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ,
Thompson RH, Tollefson MK (2014) Pretreatment neutrophil-to-
lymphocyte ratio is associated with advanced pathologic tumor stage and
increased cancer-specific mortality among patients with urothelial
carcinoma of the bladder undergoing radical cystectomy. Eur Urol 66(6):
1157–1164.
Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med
352(10): 1011–1023.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Blood count biomarkers for cystectomy
212 www.bjcancer.com |DOI:10.1038/bjc.2015.432
